[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Randomized, Double Blind, Placebo controlled, dose assessment phase II study to
evaluate the safety and efficacy of CCX168 in subjects with anti-neutrophil cytoplasmic antibody (ANCAAssociated

What is the purpose of the study?

The main safety objective of this study is to evaluate the safety and tolerability of CCX168 when it is given to patients who are receiving the standard therapy for AAV.
This study will also assess the efficacy of the treatment with CCX168 in combination with the standard therapy in the treatment of AAV.
This study will also evaluate if CCX168 improves your symptoms, your kidney function (if you have kidney disease involvement) and your overall disease activity when compared to the treatment with placebo (“sugar pills”)

Upstate Institutional Review Board (IRB) Number:


Study/Protocol ID:

Protocol CL003_168

Study Phase:

Phase II

Patient Age Group:


Principal Investigator:

Sriram S Narsipur

Who can I contact for more information?

Name: Linda L Spillett, CCRP
Phone: 315-464-9017
Email: spilletl@upstate.edu

Return to Previous Page || Search Again